journal article·2024-05

Mitocytosis Mediated by an Enzyme‐Activable Mitochondrion‐Disturbing Polymer‐Drug Conjugate Enhances Active Penetration in Glioblastoma Therapy

Yufan Xiang, Bing Wang, Wanchun Yang, Xiuli Zheng, Rongjun Chen, Qiyong Gong, Zhongwei Gu, Yanhui Liu, Kui Luo

Advanced Materials· Volume 36· Issue 18
Publisher page

Abstract

Abstract The application of nanomedicines for glioblastoma (GBM) therapy is hampered by the blood–brain barrier (BBB) and the dense glioblastoma tissue. To achieve efficient BBB crossing and deep GBM penetration, this work demonstrates a strategy of active transcellular transport of a mitochondrion‐disturbing nanomedicine, pGBEMA22‐b‐pSSPPT9 (GBEPPT), in the GBM tissue through mitocytosis. GBEPPT is computer‐aided designed and prepared by self‐assembling a conjugate of an amphiphilic block polymer and a drug podophyllotoxin (PPT). When GBEPPT is delivered to the tumor site, overexpressed γ‐glutamyl transpeptidase (GGT) on the brain–blood endothelial cell, or the GBM cell triggered enzymatic hydrolysis of γ‐glutamylamide on GBEPPT to reverse its negative charge to positive. Positively charged GBEPPT rapidly enter into the cell and target the mitochondria. These GBEPPT disturb the homeostasis of mitochondria, inducing mitocytosis‐mediated extracellular transport of GBEPPT to the neighboring cells via mitosomes. This intracellular‐to‐intercellular delivery cycle allows GBEPPT to penetrate deeply into the GBM parenchyma, and exert sustainable action of PPT released from GBEPPT on the tumor cells along its penetration path at the tumor site, thus improving the anti‐GBM effect. The process of mitocytosis mediated by the mitochondrion‐disturbing nanomedicine may offer great potential in enhancing drug penetration through malignant tissues, especially poorly permeable solid tumors.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Neurosurgery Department of Radiology Neurosurgery Research Laboratory Huaxi MR Research Center (HMRRC) Frontiers Science Center for Disease‐Related Molecular Network State Key Laboratory of Biotherapy West China Hospital Sichuan University Chengdu 610041 China

Department of Chemical Engineering Imperial College London, South Kensington Campus London SW7 2AZ UK

Functional and Molecular Imaging Key Laboratory of Sichuan Province and Research Unit of Psychoradiology Chinese Academy of Medical Sciences Chengdu 610041 China

Department of Radiology West China Xiamen Hospital of Sichuan University Xiamen 361021 China

Funding

National Natural Science Foundation of China · National Key Research and Development Program of China · West China Hospital, Sichuan University

References (76)

Show source-provided references
1. 10.1001/jama.2023.002310.1001/jama.2023.0023 ↗
2. 10.1038/s41571-020-00447-z10.1038/s41571-020-00447-z ↗
3. 10.1126/science.abm445910.1126/science.abm4459 ↗
4. 10.1038/s41551-022-00938-710.1038/s41551-022-00938-7 ↗
5. 10.1093/neuonc/noab13310.1093/neuonc/noab133 ↗
6. 10.1016/j.apsb.2022.09.01610.1016/j.apsb.2022.09.016 ↗
7. 10.1021/acs.jmedchem.1c0178410.1021/acs.jmedchem.1c01784 ↗
8. 10.1021/nn501292z10.1021/nn501292z ↗
9. 10.34172/bi.2022.2632110.34172/bi.2022.26321 ↗
10. 10.1038/s41563-023-01481-910.1038/s41563-023-01481-9 ↗
11. 10.1038/nrc189310.1038/nrc1893 ↗
12. 10.1093/jnci/djm13510.1093/jnci/djm135 ↗
13. 10.1158/1078-0432.CCR-04-233210.1158/1078-0432.CCR-04-2332 ↗
14. 10.1016/j.molmed.2023.01.00210.1016/j.molmed.2023.01.002 ↗
15. 10.1038/s41557-021-00866-010.1038/s41557-021-00866-0 ↗
16. 10.1038/s41392-021-00724-y10.1038/s41392-021-00724-y ↗
17. 10.1002/smll.20230307310.1002/smll.202303073 ↗
18. 10.1002/adma.20230366010.1002/adma.202303660 ↗
19. 10.1002/adma.20220004810.1002/adma.202200048 ↗
20. 10.1016/j.bioactmat.2023.02.01510.1016/j.bioactmat.2023.02.015 ↗
21. 10.1039/C8BM00095F10.1039/C8BM00095F ↗
22. 10.1126/science.610151110.1126/science.6101511 ↗
23. 10.1111/j.1432-1033.1991.tb16391.x10.1111/j.1432-1033.1991.tb16391.x ↗
24. 10.1016/j.biomaterials.2018.04.05310.1016/j.biomaterials.2018.04.053 ↗
25. 10.2174/15748891179593391010.2174/157488911795933910 ↗
26. 10.1038/s41467-023-40280-310.1038/s41467-023-40280-3 ↗
27. 10.1016/j.biomaterials.2023.12221310.1016/j.biomaterials.2023.122213 ↗
28. 10.1038/s41565-019-0485-z10.1038/s41565-019-0485-z ↗
29. 10.1002/smll.20200417210.1002/smll.202004172 ↗
30. 10.1016/j.addr.2021.11402710.1016/j.addr.2021.114027 ↗
31. 10.1021/acsnano.2c0633710.1021/acsnano.2c06337 ↗
32. 10.1039/C4CS00487F10.1039/C4CS00487F ↗
33. 10.1016/j.apsb.2021.08.02110.1016/j.apsb.2021.08.021 ↗
34. 10.1002/wnan.167010.1002/wnan.1670 ↗
35. 10.1002/adma.20220120010.1002/adma.202201200 ↗
36. 10.1021/acs.langmuir.0c0321710.1021/acs.langmuir.0c03217 ↗
37. 10.1002/advs.20210274110.1002/advs.202102741 ↗
38. 10.1016/j.apsb.2022.06.00910.1016/j.apsb.2022.06.009 ↗
39. 10.1016/j.jconrel.2013.10.00210.1016/j.jconrel.2013.10.002 ↗
40. 10.1016/j.bioactmat.2020.05.00110.1016/j.bioactmat.2020.05.001 ↗
41. 10.1016/j.msec.2020.11177410.1016/j.msec.2020.111774 ↗
42. 10.1039/C8CS00805A10.1039/C8CS00805A ↗
43. 10.1016/j.biomaterials.2020.11978310.1016/j.biomaterials.2020.119783 ↗
44. 10.1080/21655979.2021.200656810.1080/21655979.2021.2006568 ↗
45. 10.1021/acsami.5b1173010.1021/acsami.5b11730 ↗
46. 10.1002/adma.20220801810.1002/adma.202208018 ↗
47. 10.1016/j.biomaterials.2022.12142810.1016/j.biomaterials.2022.121428 ↗
48. 10.7150/thno.8785410.7150/thno.87854 ↗
49. 10.1016/j.bioactmat.2020.08.01710.1016/j.bioactmat.2020.08.017 ↗
50. 10.1016/j.addr.2018.07.00310.1016/j.addr.2018.07.003 ↗
51. 10.1161/CIRCRESAHA.119.31615910.1161/CIRCRESAHA.119.316159 ↗
52. 10.1021/acs.nanolett.9b0321110.1021/acs.nanolett.9b03211 ↗
53. 10.1016/j.placenta.2020.07.00610.1016/j.placenta.2020.07.006 ↗
54. 10.3402/jev.v3.2464110.3402/jev.v3.24641 ↗
55. 10.1161/hh2201.10034110.1161/hh2201.100341 ↗
56. 10.1002/cyto.a.2356710.1002/cyto.a.23567 ↗
57. 10.2147/IJN.S28248910.2147/IJN.S282489 ↗
58. 10.1016/j.cell.2021.04.02710.1016/j.cell.2021.04.027 ↗
59. 10.1016/j.cub.2018.01.00410.1016/j.cub.2018.01.004 ↗
60. 10.1038/cr.2014.13510.1038/cr.2014.135 ↗
61. 10.1038/s41556-019-0358-610.1038/s41556-019-0358-6 ↗
62. 10.1186/s12964-023-01121-410.1186/s12964-023-01121-4 ↗
63. 10.1038/cr.2015.8910.1038/cr.2015.89 ↗
64. 10.1038/s41587-018-0001-210.1038/s41587-018-0001-2 ↗
65. 10.1186/s13395-021-00274-510.1186/s13395-021-00274-5 ↗
66. 10.1016/j.kint.2019.11.02610.1016/j.kint.2019.11.026 ↗
67. 10.1200/JCO.1992.10.2.26410.1200/JCO.1992.10.2.264 ↗
68. 10.1126/scitranslmed.abf703610.1126/scitranslmed.abf7036 ↗
69. 10.1002/adma.20210477910.1002/adma.202104779 ↗
70. 10.1002/anie.20160373110.1002/anie.201603731 ↗
71. 10.1016/j.bbi.2022.02.03010.1016/j.bbi.2022.02.030 ↗
72. 10.1016/j.bbi.2011.01.00710.1016/j.bbi.2011.01.007 ↗
73. 10.1016/S0140-6736(87)91823-X10.1016/S0140-6736(87)91823-X ↗
74. 10.1039/D0NP00041H10.1039/D0NP00041H ↗
75. 10.1016/j.bmc.2017.11.02610.1016/j.bmc.2017.11.026 ↗
76. 10.1016/0092-8674(78)90132-010.1016/0092-8674(78)90132-0 ↗